serum glutathion reductas cystic fibrosi serum glutathion reductas nadphgssg oxidoreductas ec 1642 gr ha examin cystic fibrosi subject cf oblig cf heterozygot control subject serum protein concentr wa similar three group regardless unit use express activ milligram protein millilit serum whether sampl dialyz water phosphat buffer mean serum gr cf wa greater control subject p less equal 0002 seri sever year abov assay condit differ serum gr control subject carrier wa detect calcul assay valu combin control cf sera agre expect observ 50 activ 12 sera dilut cf control subject carrier addit fad incub media effect enzym activ three group differ cf control subject persist dialysi membran permit passag molecul approxim 12000 mol wt less find would tend exclud effect extran serum factor explain differ cf control subject percentag initi gr activ four day storag 04 degre wa significantli greater cf control subject p less 0025 effect heparin serum gr wa record percentag activ incub heparin vs activ standard assay individu subject effect incub 5 mugml heparin serum gr activ wa greater control subject carrier p less 00005 cf p less 00005 mean serum gr activ cf carrier wa unaffect heparin wherea mean activ control subject wa decreas control wa percentag initi activ heparin greater mean cf carrier group onli 3 20 cf 4 20 carrier individu percentag lower control mean cf carrier distribut clearli differ control distribut serum gr wa determin seven noncf individu chronic obstruct pulmonari diseas copd activ copd wa differ cf differ control subject none control copd wa serum gr great cf mean serum gr cf wa low mean control subject copd conclud serum gr activ greater cf control subject carrier noncf copd subject differ activ attribut extran serum factor activ differ secondari chronic respiratori diseas comparison control subject gr cf serum behav differ storag serum gr cf carrier behav differ control gr presenc heparin